Screener
Allogene Therapeutics ALLO Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Allogene Therapeutics’s 10-Q, filed August 12, 2026.
- Filed
- Aug 12, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-056213
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest expense | (343) | (268) | (643) | (418) |
| Other income (expenses), net | (61) | (43) | 151 | 49 |
| Total other income (expenses), net | 4,243 | 5,876 | 7,728 | 11,334 |
| Net loss | (42,677) | (50,943) | (85,284) | (110,676) |
| Other comprehensive income (loss): | ||||
| Net unrealized gain (loss) on available-for-sale investments | (335) | (88) | (787) | 44 |
| Net comprehensive loss | $(43,012) | $(51,031) | $(86,071) | $(110,632) |
| Net loss per share, basic and diluted | $(0.13) | $(0.23) | $(0.30) | $(0.51) |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's net income?
- Allogene Therapeutics (ALLO) reported net income of -$42.68M in Q2 2026.
- How has Allogene Therapeutics's net income changed year-over-year?
- Allogene Therapeutics's net income increased by 16.2% year-over-year, from -$50.94M to -$42.68M.
- What is the long-term trend for Allogene Therapeutics's net income?
- Over 4 years (2021 to 2025), Allogene Therapeutics's net income has grown at a 1.2% compound annual growth rate (CAGR), from -$182.14M to -$190.89M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Allogene Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude